Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Rule 8.3-Angle Plc

12 May 2008 13:20

RNS Number : 2093U
Kaupthing Bank hf
12 May 2008
 
FORM 8.3
DEALINGS BY PERSONS WITH INTERESTS IN SECURITIES REPRESENTING 1% OR MORE
(Rule 8.3 of the Takeover Code)
 
 
1. KEY INFORMATION
 
Name of person dealing (Note 1)
Kaupthing Bank hf
Company dealt in
Angle Plc
Class of relevant security to which the dealings being disclosed relate(Note 2)
Ordinary Shares
Date of dealing
09 May 2008
 
 
2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE
 
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
 
 
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
9,418 (0.03%)
(2) Derivatives (other than options)
 
1,017,125 (3.75 %)
 
1,017,125 (3.75 %)
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
1,017,707 (3.75 %)
 
1,026,543 (3.78 %)
 
 
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
 
Class of relevant security:
 
Long
Short
 
 
Number (%)
Number (%)
(1) Relevant securities
 
 
 
(2) Derivatives (other than options)
 
 
 
(3) Options and agreements to purchase/sell
 
 
 
Total
 
 
 
 
(c) Rights to subscribe (Note 3)
 
Class of relevant security:
 
Details
 
 
 
 
 
3. DEALINGS (Note 4)
 
(a) Purchases and sales 
 
Purchase/sale
 
Number of securities
Price per unit (Note 5)
Sell
10,000
39.50p
 
 
 
 (b) Derivatives transactions (other than options)
 
Product name,
e.g. CFD
Long/short (Note 6)
Number of securities (Note 7)
Price per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
 
Product name,
e.g. call option
 
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise
price
Type, e.g. American, European etc.
Expiry
date
Option money
paid/received per unit (Note 5)
 
 
 
 
 
 
 
 
 
 
 
 
(ii) Exercising
 
Product name, e.g. call option
Number of securities
Exercise price per unit (Note 5)
 
 
 
 
 
 
(d) Other dealings (including new securities) (Note 4)
 
Nature of transaction (Note 8)
 
Details
Price per unit (if applicable)(Note 5)
 
 
 
 
 
 
4. OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. 
No voting rights on CFD holdings
 
 
 
Is a Supplemental Form 8 attached? (Note 9) NO
 
 
Date of disclosure
12 May 2008
Contact name
Richard Easton
Telephone number
0203 205 6620
If a connected EFM, name of offeree/offeror with which connected
 
If a connected EFM, state nature of connection (Note 10)
 
 
 
Notes
 
The Notes on Form 8.3 can be viewed on the Takeover Panel’s website at www.thetakeoverpanel.org.uk
 
 
This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETXLLFFVEBFBBD
Date   Source Headline
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights
27th Feb 20127:00 amRNSParsortix Research Partnership
22nd Feb 20127:00 amRNSSecond Novocellus Patent
26th Jan 20127:00 amRNSInterim Results
26th Jan 20127:00 amRNSNovocellus Update
26th Jan 20127:00 amRNSFundraising
23rd Jan 20127:01 amRNSParsortix Update
19th Jan 20127:00 amRNSNotice of Interim Results and Webcast
16th Dec 20117:00 amRNSParsortix Update - Validation for Lung Cancer
7th Dec 20117:00 amRNSParsortix Update
21st Nov 20117:00 amRNSShare Options
16th Nov 20117:00 amRNSNovocellus Update
15th Nov 20117:00 amRNSIssue of equity and Total Voting Rights
11th Nov 20117:00 amRNSValidation for Prostate Cancer
10th Nov 20117:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.